Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Macaya, Carlos (6506673631)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Cobalt-Chromium KAname™ coRonary stEnt System in the treatment of patients with coronary artery disease (kare study)
    (2014)
    Carrie, Didier (7006798967)
    ;
    Schächinger, Volker (7003997927)
    ;
    Danzi, Gian Battista (57209549829)
    ;
    Macaya, Carlos (6506673631)
    ;
    Zeymer, Uwe (7005045618)
    ;
    Putnikovic, Biljana (6602601858)
    ;
    Iniguez, Andres (7005329352)
    ;
    Moreno, Raul (6506647911)
    ;
    Mehmedbegovic, Zlatko (55778381000)
    ;
    Beleslin, Branko (6701355424)
    Objectives To evaluate the safety and effectiveness of the Kaname™ cobalt-chromium (Co-Cr), thin strut, bare metal stent (BMS) system for the treatment of coronary artery lesions.; Background Despite widespread use of drug-eluting stents, a certain percentage of patients with coronary artery disease are still treated with BMS. Therefore, it is essential to evaluate their clinical performance.; Methods Two hundred eighty-two patients were enrolled in this prospective, single-arm study including a predefined subset of 79 patients with small vessels. The primary end-point was freedom from target vessel failure (TVF) at 6 months. Key angiographic and intravascular ultrasound (IVUS) end-points were late loss, diameter stenosis, binary restenosis, and neointimal hyperplasia volume.; Results Freedom from TVF at 6 months was 93.3% and at 1 year 90.8% in total population, and 92.4% and 87.3% in small vessels, respectively. Clinically driven target lesion revascularization (TLR) rates at 6 and 12 months were 4.3% and 6.4% in total population, and 3.8% and 7.6% in small vessels, respectively. At 6 months in-stent late loss was 0.75 plusmn; 0.43 mm and binary restenosis rate was 16.9% in total population, and 0.64 plusmn; 0.40 mm and 26.1% in small vessels, while IVUS assessed neointimal hyperplasia volume at 6 months was 128.9 plusmn; 42.6 mm3 for total population. There were no definite and probable stent thromboses up to 12 months.; Conclusions Results indicate good safety and effectiveness of the Kaname™ stent with clinically equivalent results in small and larger vessels, as such providing useful treatment option for patients with ischemic heart disease considered for BMS implantation. (J Interven Cardiol 2014;27:491-499) © 2014, Wiley Periodicals, Inc.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback